Crizotinib was the first small molecule c-Met inhibitor approved in 2011 for treatment of non-small cell lung cancer (NSCLC), which was followed later by approval of cabozantinib for management of metastatic medullary thyroid cancer and very recently capmatinib for treatment of NSCLC10–12. This evidence concerns the gene MET and non-small cell lung carcinoma.